ACP
PFE icon

Argyle Capital Partners’s Pfizer PFE Stock Holding History

Argyle Capital Partners’s Portfolio PFE Stock Details PFE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$323K Sell
13,411
-1,099
-8% -$28.7K 0.2% 126
2026
Q1 		$407K Buy
14,510
+606
+4% +$16.1K 0.29% 96
2025
Q4 		$346K Buy
13,904
+1,261
+10% +$31.8K 0.25% 105
2025
Q3 		$322K Sell
12,643
-1,330
-10% -$32.8K 0.23% 121
2025
Q2 		$339K Buy
13,973
+1,686
+14% +$39.3K 0.28% 102
2025
Q1 		$311K Sell
12,287
-1,795
-13% -$47K 0.27% 99
2024
Q4 		$374K Buy
+14,082
New +$382K 0.32% 89

Other funds holding PFE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Argyle Capital Partners's PFE Position: Q2 2026 in Review

Argyle Capital Partners reduced its Pfizer (PFE) stake by 7.6% in Q2 2026, selling an estimated $28.7K and leaving 13,411 shares worth $323K. The position accounts for 0.2% of the portfolio, ranked #126.

Argyle Capital Partners first reported a position in PFE in Q4 2024 and has held it in 7 quarters since. The position peaked at $407K in Q1 2026. 2,831 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • Argyle Capital Partners held 13,411 shares of Pfizer worth $323K as of Q2 2026.
  • Argyle Capital Partners sold 1,099 Pfizer shares in Q2 2026, an estimated $28.7K.
  • Pfizer made up 0.2% of Argyle Capital Partners's portfolio in Q2 2026, its #126 holding.
  • Argyle Capital Partners first reported a position in Pfizer in Q4 2024 and has held it in 7 quarters since.
  • Argyle Capital Partners's Pfizer position peaked at $407K in Q1 2026.
  • 2,831 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Argyle Capital Partners's 13F filing for Q2 2026, filed 7 Aug 2026.